8-K: Semnur Pharmaceuticals Updates Securities, Governance Post-Merger

Sentiment:

Corporate Governance Update 3 December 2025 4:20 PM

📋All filings for Denali Capital Acquisition CORP

Semnur Pharmaceuticals, Inc. filed an 8-K to update its securities description and corporate governance following its September 2025 business combination.

Worse than expectedThe company's securities were suspended from trading on The Nasdaq Capital Market, a major exchange, and subsequently began trading on the OTCQB marketplace, which generally has lower liquidity and visibility.

Summary

Semnur Pharmaceuticals, Inc. filed an 8-K to update the description of its securities and reflect amendments to its Certificate of Incorporation and Bylaws since December 31, 2024.
The company consummated a business combination on September 22, 2025, with Legacy Semnur (now Semnur, Inc.), previously operating as Denali Capital Acquisition Corp.
As of December 3, 2025, Semnur has 229,740,978 shares of Common Stock and 5,423,606 shares of Series A Preferred Stock issued and outstanding.
The Series A Preferred Stock, issued to Scilex Holding Company, ranks senior to Common Stock in liquidation and dividend rights, and has specific voting and protective provisions.
The company has 8,250,000 Public Warrants and 510,000 Private Warrants outstanding, each exercisable at $11.50 per share, expiring five years from the business combination.
Semnur's securities were suspended from trading on The Nasdaq Capital Market on April 16, 2025, and subsequently began trading on the OTCQB marketplace on April 17, 2025, under new symbols (SMNR, SMNRW) after the business combination.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting from Nasdaq and subsequent trading on OTCQB, which is generally perceived as a downgrade. While the business combination is complete, the governance details are largely defensive (anti-takeover) and the risks associated with warrant dilution and market price impact are noted.

Positives

Completion of the business combination on September 22, 2025, which was previously announced.
The company has a clear framework for its capital structure, including authorized common and preferred stock, and outstanding warrants.

Negatives

Suspension of trading from The Nasdaq Capital Market on April 16, 2025.
Relisting of securities on the OTCQB marketplace, which typically implies lower liquidity and less stringent listing requirements compared to Nasdaq.

Risks

The presence of additional shares of common stock trading in the public market due to registration rights may have an adverse effect on the market price of Semnur's securities.
The issuance of preferred stock could adversely affect the voting power or other rights of common stock holders and may delay, defer, or prevent a change in control.
Anti-takeover provisions in the Charter and Bylaws, such as a classified board, restrictions on director removal and vacancy filling (after Trigger Event), and limitations on stockholder actions, could delay or discourage attempts to acquire Semnur, potentially depriving stockholders of opportunities to sell shares at a premium.
The exclusive forum provisions in the Charter may discourage lawsuits against Semnur's directors and officers, and their enforceability has been challenged in legal proceedings.
Limitation of liability and indemnification provisions for directors and officers may discourage stockholders from bringing lawsuits for breach of fiduciary duty and could adversely affect stockholder investment if the company pays settlement and damage awards.
Warrants may have no value and expire worthless if the registration statement covering the underlying common stock is not current or if the common stock is not qualified or exempt from qualification in relevant jurisdictions.
The market for warrants may be limited if the prospectus is not current.

Future Outlook

The filing describes the company's capital structure and governance framework post-business combination, but does not provide specific forward-looking statements or guidance on financial performance or operational targets.

Industry Context

This filing is primarily focused on corporate structure and governance updates following a business combination and a change in listing venue. It does not provide information to analyze broader industry trends or competitive positioning.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Charter Amendment	The Charter authorizes 740,000,000 shares of Common Stock and 45,000,000 shares of undesignated Preferred Stock, with 5,423,606 shares designated as Series A Preferred Stock.	2025-09-22	Provides flexibility for future capital raises and strategic transactions, but preferred stock issuance could dilute common stockholders' rights and deter takeovers.
Bylaws Amendment	The Board is divided into three classes with staggered three-year terms, making it more difficult for stockholders to replace a majority of directors.	2025-09-22	Enhances board stability but acts as an anti-takeover measure, potentially reducing stockholder influence over board composition.
Bylaws Amendment	Directors may be removed with or without cause by majority vote, but after a 'Trigger Event' (Scilex owning <= 50% voting power), removal requires cause and 66 2/3% vote.	2025-09-22	Strengthens board's defense against hostile takeovers post-Scilex's majority control, potentially limiting stockholder ability to effect change.
Bylaws Amendment	Vacancies on the Board are filled by a majority of directors, but after a 'Trigger Event', stockholders cannot fill vacancies.	2025-09-22	Further entrenches the existing board's control over its composition after Scilex's majority control diminishes.
Charter Amendment	The company has opted out of Section 203 of the DGCL until a 'Trigger Event', after which it will automatically become governed by it, prohibiting business combinations with 'interested stockholders' for three years.	2025-09-22	Provides a temporary exemption for Scilex, but establishes a standard anti-takeover defense once Scilex's ownership falls below 50%, potentially limiting future acquisition opportunities.
Charter Amendment	The Charter does not authorize cumulative voting, meaning stockholders holding a majority of voting shares can elect all directors.	2025-09-22	Concentrates voting power, making it harder for minority stockholders to elect directors.
Bylaws Amendment	Special stockholder meetings can only be called by the Chairman, Board, or CEO, though Scilex can request them prior to a 'Trigger Event'.	2025-09-22	Restricts stockholders' ability to call special meetings, limiting their capacity to address urgent matters or initiate changes.
Bylaws Amendment	Advance notice procedures are established for stockholder proposals and director nominations.	2025-09-22	Ensures orderly meetings but can deter last-minute challenges to management or board nominations.
Charter Amendment	Stockholder action by written consent is generally not permitted, requiring a meeting, but is allowed prior to a 'Trigger Event' if signed by the minimum required votes.	2025-09-22	Limits stockholder ability to act quickly without a formal meeting, increasing the time and effort required for significant corporate actions post-Scilex's majority control.
Charter Amendment	After a 'Trigger Event', amending certain key anti-takeover provisions of the Charter requires an affirmative vote of at least 66 2/3% of the voting power.	2025-09-22	Makes it significantly harder to dismantle anti-takeover defenses once Scilex's majority control diminishes, further entrenching current governance.
Charter Amendment	The Charter establishes Delaware Court of Chancery as the exclusive forum for certain corporate claims and federal district courts for Securities Act claims.	2025-09-22	Aims for consistency in legal interpretations but may discourage lawsuits against directors and officers, potentially limiting stockholder recourse.
Charter Amendment	Limits the liability of directors and officers for monetary damages to the fullest extent permitted by DGCL and provides for indemnification.	2025-09-22	Helps attract and retain qualified personnel but may reduce accountability and shift potential legal costs to the company and its stockholders.
Charter Amendment	The Charter includes provisions renouncing corporate opportunities for 'Identified Persons' in similar business activities.	2025-09-22	Allows certain individuals to pursue opportunities that might otherwise be considered corporate, potentially diverting value from the company.

Related Party Transactions

5,423,606 shares of Series A Preferred Stock have been issued to Scilex Holding Company (Scilex) pursuant to the terms of the Merger Agreement.
The Charter provides that the restrictions on business combination of Section 203 of the DGCL do not apply to Scilex or its current or future Affiliates, regardless of their ownership percentage.
Prior to the 'Trigger Event' (Scilex owning <= 50% voting power), special meetings of stockholders can be called at Scilex's request, and the Board cannot postpone, reschedule, or cancel such meetings without Scilex's consent.

Stakeholder Impact

Shareholders: Common stockholders face potential dilution from warrant exercises and the public sale of registrable securities. Their voting power and rights may be affected by the existence of preferred stock and anti-takeover provisions. The delisting from Nasdaq to OTCQB may impact liquidity and market visibility.
Scilex Holding Company: As a holder of Series A Preferred Stock, Scilex has significant protective rights, including senior ranking in liquidation and dividends, specific voting rights, and influence over corporate actions prior to a 'Trigger Event.'
Directors and Officers: Benefit from limited liability and indemnification provisions, which aim to attract and retain qualified individuals but may reduce their personal accountability.

Next Steps

Semnur is required to file and maintain an effective registration statement under the Securities Act covering the resale of all registrable securities.
The Board will continue to determine the total number of directors from time to time.
The company will hold its first annual meeting of stockholders after January 1, 2026.

Key Dates

Date	Description
2022-04-06	Date of Warrant Agreement between the Company and VStock Transfer, LLC.
2024-08-30	Date of the original Agreement and Plan of Merger.
2024-12-31	End of the Company's fiscal year, after which amendments to Certificate of Incorporation and Bylaws are being updated.
2025-04-16	Amendment No. 1 to Agreement and Plan of Merger dated; Registrant's securities suspended from trading on The Nasdaq Capital Market.
2025-04-17	Registrant's securities began trading on the OTCQB marketplace under symbols DNQAF, DNQWF, and DNQUF.
2025-07-22	Amendment No. 2 to Agreement and Plan of Merger dated.
2025-09-22	Consummation of the business combination; Date of Amended and Restated Registration Rights Agreement.
2025-09-23	Registrant's securities began trading on the OTCQB marketplace under symbols SMNR and SMNRW.
2025-09-26	Date of Current Report on Form 8-K filed with the SEC, which includes copies of the Charter and Bylaws.
2025-12-03	Date of this Current Report on Form 8-K; Date as of which outstanding shares of Common Stock and Series A Preferred Stock are reported.
2030-09-22	Approximate expiration date of warrants (five years from business combination consummation on September 22, 2025).

Recommendation

hold

The filing primarily details corporate structure and governance changes post-merger, along with the negative development of delisting from Nasdaq. While the completion of the business combination is a positive, the move to OTCQB and the extensive anti-takeover provisions, coupled with potential dilution from warrants, create uncertainty. Without financial performance data or strategic updates, a 'hold' recommendation is appropriate as investors await clearer operational direction and financial results from the newly combined entity.

Keywords

Semnur Pharmaceuticals, 8-K filing, securities description, corporate governance, business combination, common stock, preferred stock, warrants, OTCQB, Nasdaq delisting, anti-takeover provisions, registration rights, Scilex Holding Company

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.